Predicting disease‐specific survival in patients undergoing active surveillance for papillary thyroid carcinoma
World Journal of Surgery · 2025
DOI: 10.1002/wjs.12434 ↗At a glance
Journal article in World Journal of Surgery, 2025. Written by Stanton Nielsen and 8 co-authors. Institution: Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA. Major MEDLINE topics: Thyroid Neoplasms, Thyroid Cancer, Papillary, Watchful Waiting. Cited 2 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
American Thyroid Association guidelines support active surveillance (AS) for low‐risk papillary thyroid cancer (PTC). We developed a calculator to aid patient selection.
Methods
From 2004 to 2020, 148,904 PTC patients were selected from the surveillance, epidemiology, and end results (SEER) database. Univariable and multivariable analysis evaluated patient and treatment characteristics. Patients were randomly allocated into training (80%) or validation sets (20%). Coefficients generated a mathematical model to predict 5‐ and 10‐year disease‐specific survival (DSS).
Results
The mean DSS was 15.5 years with a 5‐ and 10‐year DSS of 99.3% and 98.6%, respectively. Age, sex, race, median household income (MHI), tumor size, and nodal status were significant on multivariable analysis ( p ≤ 0.05) and included variables in our calculator. 2404 patients underwent non‐operative management (NOM) and were more likely older, male, higher MHI, larger tumor size, and less nodal positivity. Area under the curve (AUC) for 5‐ and 10‐year DSS were 0.83 and 0.81, respectively, for the training set and 0.81 and 0.79, respectively, for the validation set. Example 65‐year‐old White female with a 0.8 cm PTC, cN0 with a MHI ≥ $75,000, had a 10‐year predicted DSS was 95.6% with NOM and 99.3% with surgery. Alternatively, changing the patient's race to Hispanic, the 10‐year predicted DSS was 94.1% with NOM and 99.0% with surgery.
Conclusions
As awareness of AS for PTC expands, it is important to consider objective data to guide informed decision making. This validated calculator is a useful tool to predict DSS for patients considering AS for PTC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA.
- The University of Chicago Medical Center Chicago, Chicago, IL, USA.
- Department of Surgery, University of Wisconsin-Madison, Madison, WI, USA.
- Department of Surgery, John H. Stroger Jr, Hospital of Cook County, Chicago, IL, USA.
ORCID profiles: Stanton Nielsen
Cite
APA
Nielsen, S., Kuchta, K., Huang, G., Zuber, S., Holoubek, S., Karcioglu, A., Khokar, A., Prinz, R., & Moo-Young, T. (2025). Predicting disease‐specific survival in patients undergoing active surveillance for papillary thyroid carcinoma. World Journal of Surgery. https://doi.org/10.1002/wjs.12434
Vancouver
Nielsen S, Kuchta K, Huang G, Zuber S, Holoubek S, Karcioglu A, et al. Predicting disease‐specific survival in patients undergoing active surveillance for papillary thyroid carcinoma. World Journal of Surgery. 2025. doi:10.1002/wjs.12434
BibTeX
@article{Nielsen2025,
author = {Nielsen, Stanton and Kuchta, Kristine and Huang, Grace and Zuber, Samuel and Holoubek, Simon and Karcioglu, Amanda and Khokar, Amna and Prinz, Richard and Moo-Young, Tricia},
title = {Predicting disease‐specific survival in patients undergoing active surveillance for papillary thyroid carcinoma},
journal = {World Journal of Surgery},
year = {2025},
doi = {10.1002/wjs.12434}
}
EUVIMED